The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy

SIMPLE SUMMARY: Combining chemoradiotherapy with immunotherapy is one of the main milestones in cancer treatment. The optimal sequence to ensure the effectiveness of the treatment is unknown. We investigated the kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L), a multi-potential haemopoieti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuncman, Łukasz, Orzechowska, Magdalena, Stawiski, Konrad, Masłowski, Michał, Ciążyńska, Magdalena, Gottwald, Leszek, Milecki, Tomasz, Fijuth, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405787/
https://www.ncbi.nlm.nih.gov/pubmed/36010838
http://dx.doi.org/10.3390/cancers14163844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405787/
https://www.ncbi.nlm.nih.gov/pubmed/36010838
http://dx.doi.org/10.3390/cancers14163844

Ejemplares similares